JD-5037,98.0%
产品编号:Bellancom-18697| CAS NO:1392116-14-1| 分子式:C27H27Cl2N5O3S| 分子量:572.51
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
JD-5037
| 产品介绍 | JD-5037 是 CB1R 有效拮抗剂,IC50 值为 1.5 nM。 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 生物活性 | JD-5037 is a potent CB1R antagonist with an IC50 of 1.5 nM.  | ||||||||||||||||
| 体外研究 | |||||||||||||||||
| 体内研究 |                                         
                                        
                                             JD5037 (3 mg/kg/d, i.p.) induces equal reductions in body weight, attenuates the HFD-induced hyperglycemia, and reduces the HFD-induced hepatic injury and steatosis in obese Magel2-null mice. JD5037 (3 mg/kg/day, p.o.) significantly reduces the size of tumors and abrogates the tumor in DEN-treated mice. JD5037 attenuates the AEA levels in HCC samples from mice. 西域 has not independently confirmed the accuracy of these methods. They are for reference only.  | ||||||||||||||||
| 体内研究 |                                         
                                        
                                             JD5037 (3 mg/kg/d, i.p.) induces equal reductions in body weight, attenuates the HFD-induced hyperglycemia, and reduces the HFD-induced hepatic injury and steatosis in obese Magel2-null mice. JD5037 (3 mg/kg/day, p.o.) significantly reduces the size of tumors and abrogates the tumor in DEN-treated mice. JD5037 attenuates the AEA levels in HCC samples from mice. 西域 has not independently confirmed the accuracy of these methods. They are for reference only.  | ||||||||||||||||
| 性状 | Solid | ||||||||||||||||
| 溶解性数据 | 
                                        
                                             In Vitro:  
                                            DMSO : 250 mg/mL (436.67 mM; Need ultrasonic) 配制储备液 
                                                
 
 
                                                    *
                                                     
                                            
                                        
                                        
                                            请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 
                                            请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: 
                                                    ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
                                                        以下溶剂前显示的百 
  | ||||||||||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere.  | ||||||||||||||||
| 储存方式 | 
                                
  | ||||||||||||||||
| 参考文献 | 
  | 
                            
                                    
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                        
 
 
 
 
浙公网安备 33010802013016号